The hepatic PP1 glycogen-targeting subunit interaction with phosphorylase a can be blocked by C-terminal tyrosine deletion or an indole drug

FEBS Letters

Volumn 581, Issue 24, 2007, Pages 4749-4753

  Kelsall, Ian R ^a   Munro, Shonagh ^a   Hallyburton, Irene ^b   Treadway, Judith L ^c   Cohen, Patricia T W ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

CP 316819; Diabetes; Glycogen metabolism; Glycogen phosphorylase; Glycogen targeting subunit; Protein phosphatase 1

Indexed keywords

AMINO ACID; ANTIDIABETIC AGENT; ENZYME INHIBITOR; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; INDOLE DERIVATIVE; PHENYLALANINE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHORYLASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GLYCOGEN LIVER LEVEL; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN INTERACTION; PROTEIN TARGETING;

AMINO ACID SEQUENCE; ANIMALS; CALORIMETRY; GLYCOGEN PHOSPHORYLASE, LIVER FORM; HUMANS; INDOLES; MICE; MOLECULAR SEQUENCE DATA; MUTATION; PHENYLBUTYRATES; PROTEIN BINDING; PROTEIN SUBUNITS; RABBITS; RATS; THERMODYNAMICS; TITRIMETRY; TYROSINE;

EID: 34548697097     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.08.073     Document Type: Article

References (24)

1. DeFronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 131 (1999) 281-303
2. Roden M., and Bernroider E. Hepatic glucose metabolism in humans-its role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 17 (2003) 365-383
3. Ferrer J.C., Favre C., Gomis R.R., Fernandez-Novell J.M., Garcia-Rocha M., de la Iglesia N., Cid E., and Guinovart J.J. Control of glycogen deposition. FEBS Lett. 546 (2003) 127-132
4. Roach P.J. Glycogen and its metabolism. Curr. Mol. Med. 2 (2002) 101-120
5. Bollen M., Keppens S., and Stalmans W. Specific features of glycogen metabolism in the liver. Biochem. J. 336 (1998) 19-31
6. L) subunit of protein phosphatase-1. FEBS Lett. 375 (1995) 284-298
7. Armstrong C.G., Doherty M.J., and Cohen P.T.W. Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem. J. 336 (1998) 699-704
8. Yu L.J., Chen Y., Treadway J.L., McPherson R.K., McCoid S.C., Gibbs E.M., and Hoover D.J. Establishment of correlation between in vitro enzyme binding potency and in vivo pharmacological activity: application to liver glycogen phosphorylase a inhibitors. J. Pharmacol. Exp. Ther. 317 (2006) 1230-1237
9. Cohen P., Alemany S., Hemmings B.A., Resink T.J., Stralfors P., and Tung H.Y.L. Protein phosphatase-1 and protein phosphatase-2A from rabbit skeletal muscle. Methods Enzymol. 159 (1988) 390-408
10. Hulin, B., Hoover, D.J., Treadway, J.L. and Martin, W.H. (1996) US Patent Application WO96/39385 Published Dec. 12th Example 36.
11. Barford D., and Johnson L.N. The molecular mechanism for the tetrameric association of glycogen phosphorylase promoted by protein phosphorylation. Protein Sci. 1 (1992) 472-493
12. Leonidas D.D., Oikonomakos N.G., Papageorgiou A.C., and Sotiroudis T.G. Kinetic properties of tetrameric glycogen phosphorylase b in solution and in the crystalline state. Protein Sci. 1 (1992) 1123-1132
13. Johnson L.N., and Barford D. Glycogen phosphorylase. The structural basis of the allosteric response and comparison with other allosteric proteins. J. Biol. Chem. 265 (1990) 2409-2412
14. Moorhead G., MacKintosh C., Morrice N., and Cohen P. Purification of the hepatic glycogen-associated form of protein phosphatase-1 by microcystin-Sepharose affinity chromatography. FEBS Lett. 362 (1995) 101-105
15. Alemany S., and Cohen P. Phosphorylase a is an allosteric inhibitor of the glycogen and microsomal forms of rat hepatic protein phosphatase-1. FEBS Lett. 198 (1986) 194-202
16. Oikonomakos N.G., Zographos S.E., Skamnaki V.T., and Archontis G. The 1.76 A resolution crystal structure of glycogen phosphorylase b complexed with glucose, and CP-320626, a potential antidiabetic drug. Bioorg. Med. Chem. 10 (2002) 1313-1319
17. Ekstrom J.L., et al. Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase. Chem. Biol. 9 (2002) 915-924
18. Barford D., Hu S.H., and Johnson L.N. Structural mechanism for glycogen phosphorylase control by phosphorylation and AMP. J. Mol. Biol. 218 (1991) 233-260
19. Rath V.L., et al. Activation of human liver glycogen phosphorylase by alteration of the secondary structure and packing of the catalytic core. Mol. Cell 6 (2000) 139-148
20. Rath V.L., et al. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chem. Biol. 7 (2000) 677-682
21. Oikonomakos N.G., Chrysina E.D., Kosmopoulou M.N., and Leonidas D.D. Crystal structure of rabbit muscle glycogen phosphorylase a in complex with a potential hypoglycaemic drug at 2.0 A resolution. Biochim. Biophys. Acta 1647 (2003) 325-332
22. Baker D.J., Greenhaff P.L., Macinnes A., and Timmons J.A. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction. Diabetes 55 (2006) 1855-1861
23. Treadway J.L., Mendys P., and Hoover D.J. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus. Exp. Opin. Invest. Drugs 10 (2001) 439-454
24. L of liver. Diabetes 51 (2002) 591-598